Jaguar health reports phase 3 ontarget trial results for its cancer supportive care drug crofelemer

Initial results of unprecedented trial including 10 different tumor types indicate that ontarget did not meet its primary endpoint across all tumor types. trial did reveal clinically relevant signals for crofelemer in prespecified subgroups of patients with breast and respiratory cancer, including lung cancer.
JAGX Ratings Summary
JAGX Quant Ranking